Synonyms
- Neurontin®
Expected Turnaround Time
2 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Minimum Volume
0.3 mL
Container
Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Collection
Transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Maintain specimen at room temperature.
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Gel-barrier tube
Test Details
Methodology
Immunoassay (IA)
Reference Interval
4.0−16.0 μg/mL
Additional Information
Gabapentin (Neurontin®) is an oral antiepileptic agent that is structurally related to the neurotransmitter γ-aminobutyric acid (GABA) but it does not interact with GABA receptors in the brain. Its mechanism of action is unknown but it has properties in common with other anticonvulsant medications. Gabapentin is only 3% bound to circulating protein in the blood and is not appreciably metabolized. Gabapentin is cleared by the kidneys and has an elimination half-life of five to seven hours.1 Steady-state concentrations are reached after one to two days with the time between ingestion and maximal serum concentration being two to three hours.2 For therapeutic drug monitoring, specimens should be drawn as trough levels. There are no significant drug interactions with other anticonvulsants. Adverse reactions are not common and are confined to somnolence (1.2%), ataxia (0.8%), fatigue (0.6%), nausea or vomiting (0.6%), and dizziness (0.6%).
Footnotes
1. Drug Facts and Comparisons. 66th ed. St Louis, Mo: Wolters Kluwer Co; 2012.
2. Bourgeois BF, “Pharmacokinetic Properties of Current Antiepileptic Drugs. What Improvements Are Needed?” Neurology. 2000; 55(11 Suppl 3):S11-S16. 11147563
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 716811 | Gabapentin (Neurontin), Serum | 9738-6 | 716812 | Gabapentin, Serum | ug/mL | 9738-6 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf